2010
In this project, the researchers hypothesize that targeting apoE, a component of amyloid plaques, can result in less Aβ aggregation in the brain and decreased Aβ-related pathology and that this treatment will have fewer side effects than the use of anti-Aβ antibodies. The project will test this hypothesis in this proposal in the context of human apoE isoforms.
$100,000
Studies of APOE, Translational
David Holtzman, M.D.
Kapil V. Ramachandran, | 2023
Joel Blanchard, | 2023
David Holtzman, | 2023
Na Zhao, Yingxue Ren, | 2023
Victor Faundez, | 2023
Jean-Pierre Roussarie, | 2022
Cheryl Wellington, | 2022
David Holtzman, | 2022